Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.83 |
| ▸ | FAAH | O00519 | 4/20 | 0.78 |
| ▸ | NAAA | Q02083 | 1/20 | 0.77 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.72 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.69 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.67 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.64 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10790501 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL22271678 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL2150966 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL8368632 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL498043 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL23775006 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL21234011 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL20542645 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL21633848 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL6424205 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022108-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2026-01-22 | — | — | US | disclosed |
| EP-4559905-A2 | ISOQUINOLIN-3-YL CARBOXAMIDES AS WNT INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-12281097-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20230286945-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2023-09-14 | — | — | US | disclosed |
| US-11548872-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-3892276-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AS WNT INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| US-10947217-B2 | Isoquinolin-3-YL carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2021-03-16 | — | — | US | disclosed |
| EP-3448386-B1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | SAMUMED LLC (US) | 2021-03-03 | — | — | EP | disclosed |
| US-20200299263-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2020-09-24 | — | — | US | disclosed |
| US-10544128-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-01-28 | — | — | US | disclosed |
| US-7208254-B2 | Binding resin for toner, toner and electrophotographic apparatus | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 2007-04-24 | — | — | US | disclosed |
| US-7063929-B2 | Binding resin for toner, toner and electrophotographic apparatus | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 2006-06-20 | — | — | US | disclosed |
| US-20060127789-A1 | Binding resin for toner, toner and electrophotographic apparatus | YUASA YASUHITO | 2006-06-15 | — | — | US | disclosed |
| EP-1643311-A2 | Binding resin for toner, toner and electrophotographic apparatus | Matsushita Electric Industrial Co., Ltd. (JP) | 2006-04-05 | — | — | EP | disclosed |
| US-20060057482-A1 | Toner, two-component developer, and image forming method | MATSUSHITA ELECTRIC INDUSTRIAL CO. (JP) | 2006-03-16 | — | — | US | disclosed |
| US-20060014094-A1 | Two-component developer and method of forming image therewith | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 2006-01-19 | — | — | US | disclosed |
| US-20050196694-A1 | Toner, method for producing toner, two component developer, and image forming apparatus | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 2005-09-08 | — | — | US | disclosed |
| US-20050053858-A1 | Preparing a toner composition containing a high-molecular-weight binder resin by kneading using opposing rolls heated or cooled to different temperatures and operating at different peripheral speeds to form a low-molecular weight resin; antifogging agents; antiagglomerants; offset resistance | YUASA YASUHITO (JP) | 2005-03-10 | — | — | US | disclosed |
| US-6579653-B1 | Toner comprising binder having certain molecular weight distribution, obtained by kneading composition so that high molecular weight component is converted into low molecular weight component by thermal or mechanical energy exerted | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 2003-06-17 | — | — | US | disclosed |
| EP-1168088-A1 | BINDING RESIN FOR TONER, TONER, AND ELECTROPHOTOGRAPH | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299263-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | WNT1, WNT3, WNT3A | CASP2 961/4885FAAH 3439/4885NAAA 2943/4885 |
| US-12281097-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | WNT1, WNT3, WNT3A | CASP2 961/4885FAAH 3439/4885NAAA 2943/4885 |
| US-10544128-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | WNT1, WNT3, WNT3A | CASP2 961/4885FAAH 3439/4885NAAA 2943/4885 |
| US-10947217-B2 | Isoquinolin-3-YL carboxamides and preparation and use thereof | WNT1, WNT3, WNT3A | CASP2 961/4885FAAH 3439/4885NAAA 2943/4885 |
| US-20230286945-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | WNT1, WNT3, WNT3A | CASP2 961/4885FAAH 3439/4885NAAA 2943/4885 |
| US-11548872-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | WNT1, WNT3, WNT3A | CASP2 961/4885FAAH 3439/4885NAAA 2943/4885 |
| US-20260022108-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | WNT1, WNT3, WNT3A | CASP2 2176/4885FAAH 3392/4885NAAA 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.